What are the risks associated with taking 5 mg of folic acid daily in high‑risk pregnant women?

Risks of 5 mg Daily Folic Acid in High-Risk Pregnant Women

Taking 5 mg of folic acid daily in high-risk pregnant women is considered safe and does not mask vitamin B12 deficiency, according to established guidelines. 1

Safety Profile

The primary historical concern with high-dose folic acid has been the potential to mask pernicious anemia (vitamin B12 deficiency) by correcting hematologic abnormalities while allowing neurologic damage to progress. However, the Society of Obstetricians and Gynaecologists of Canada and Motherisk explicitly state that 5 mg of folic acid will not mask vitamin B12 deficiency 1. The FDA label cautions that doses above 0.1 mg may obscure pernicious anemia 2, but this concern is primarily relevant in non-pregnant populations and at therapeutic doses without proper screening.

Established Safety Guidelines

• No serious harms have been documented with folic acid supplementation at usual doses (0.4-0.8 mg) 3
• The 5 mg dose is specifically recommended for high-risk groups including:
  • Previous NTD-affected pregnancy
  • Personal or family history of NTDs
  • Type 1 diabetes mellitus
  • Epilepsy treatment with valproate or carbamazepine 1, 4

Emerging Safety Concerns from Recent Research

While guidelines support 5 mg dosing, very recent research (2025-2026) has identified potential associations that warrant awareness, though these do not currently change clinical recommendations:

Cancer Risk

A 2025 Scandinavian cohort study found high-dose folic acid (>1 mg daily) was associated with:

• 20% increased overall cancer risk (adjusted HR = 1.2,95% CI = 1.1-1.2)
• This attenuated to 10% after 6-month lag analysis (adjusted HR = 1.1,95% CI = 1.04-1.2)
• Consistent association with non-Hodgkin lymphoma (adjusted HR = 2.0,95% CI = 1.3-2.9) 5

Important caveat: This study included all women who gave birth, not specifically those with medical indications for high-dose supplementation, and the absolute risk remained low.

Gestational Diabetes and Fetal Outcomes

A 2026 systematic review suggested associations between excessive folic acid intake and:

• Gestational diabetes mellitus
• Adverse neurodevelopmental issues in offspring
• Large-for-gestational-age infants 6

Critical limitation: This review did not distinguish between medically indicated high-dose supplementation and excessive intake from multiple sources.

Clinical Algorithm for Safe Use

Before prescribing 5 mg folic acid:

1. Confirm high-risk indication (previous NTD, family history, diabetes, valproate/carbamazepine use) 1

2. Screen for vitamin B12 deficiency if signs/symptoms present:

   • Hypersegmentation of polymorphonuclear cells
   • Macrocytic indices
   • Leukopenia or thrombocytopenia
   • Markedly elevated LDH 4

3. Prescribe 5 mg as folic acid alone, not in multivitamin format, to avoid excessive intake of other vitamins (particularly vitamin A) 4

4. Timing: Start 3 months before conception and continue through first trimester 1

Common Pitfalls to Avoid

• Do not combine 5 mg folic acid with prenatal multivitamins containing additional folic acid—this creates excessive total intake 4
• Do not prescribe high-dose folic acid without documented indication—the emerging research suggests potential risks at doses >1 mg without clear benefit 5, 6
• Monitor compliance carefully in women on valproate or polytherapy—these groups show only 30.8% and 25.6% compliance respectively, yet have highest NTD risk 7

Drug Interactions

Phenytoin users require special attention: Folic acid antagonizes phenytoin's anticonvulsant action, potentially requiring dose adjustment to prevent breakthrough seizures 2. This creates a clinical dilemma requiring neurologist collaboration.

Bottom Line for Practice

The benefits of 5 mg folic acid in appropriately selected high-risk women substantially outweigh known risks, with strong evidence for NTD prevention and additional benefits for other congenital anomalies (cleft lip/palate, cardiac defects, urinary tract abnormalities) 1. The recent cancer and metabolic associations require further study but should not deter use in women with clear medical indications, as the absolute risks remain low and NTD prevention is life-saving. Ensure proper patient selection, avoid combining with other folic acid sources, and screen for B12 deficiency when clinically indicated.